METABOLIC PARAMETERS OF PATIENTS WITH DIABETES PRESENTING WITH ACUTE MYOCARDIAL INFARCTION

Main Article Content

Khalid Usman
Mujeeb ur Rehman
Arif Mumtaz
Naseeb UrRehman
Salman Khan

Keywords

Diabetes, Acute Myocardial Infarction, Metabolic Parameters, Clinical Management

Abstract

Background: This Study probes into metabolic parameters of diabetic patients with acute myocardial infarction (AMI) with major focus on glycemic control, lipid profiles, inflammation markers and variations across age and gender.


Objective: The study objectives are to analyze the metabolic parameters among 200 diabetic patients who have suffered from acute myocardial infarction, evaluate diabetes control of blood glucose, lipid profiles and inflammation markers as well as investigate variations across age and gender so that its results could provide insight on how to optimize management strategies.


Design: A Cross-sectional study


Place and Duration of Study: Department of Endocrinology & HMC Peshawar from Jan 2021 to July 2021


 


Methods: We analyzed 200 diabetes-related AMI cases. Metabolic parameters like fasting blood glucose (fpg), glycated hemoglobin A1c (HbA1c), lipids profile such as total cholesterol (TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), triglyceride(TG) were measured. Age-specific (25-30 years, 35-45 years, 50-65 years) and gender-specific groups were made. Information about comorbidities, medication histories and clinical outcomes were obtained. Moreover, factor analysis was carried out in order to identify the correlation between variables namely; lipid profile , fasting blood sugar , C-reactive protein , glycosylated hemoglobin level . This investigation was aimed at providing an all-rounded understanding of type II diabetics presenting with an acute MI while addressing treatment protocols.


Results: Diabetic Patients had significant differences in their metabolic parameters when assessed for Acute Myocardial Infraction (AMI). The mean age for the group is 47.5±10.3years old persons. Therefore, a Meta-regression analysis was carried out investigating all papers associated with the present topic that yielded reliable information. Analysis of metabolic parameters showed elevated fasting blood glucose levels (mean = 180 mg/dL, SD = 45.6), HbA1c levels (mean = 8.2%, SD = 1.2) as well as lipid profiles including total cholesterol mean = 240mg/dl, sd=35.5; triglycerides mean=200mg/dl, sd=40.2 whereby inflammation markers were also high CRP mean=10mg/l and sd=5.6 but comparable to our own data Statistical analysis was done to determine whether there were any differences in the body composition among different groups with respect to the independent variables mentioned above (age and gender). For this reason, it is necessary that these interventions be formally tailored for considering a certain group.


Conclusion: The metabolic derangements are well shown by AMI patients who have diabetes. These include elevated blood glucose levels, dyslipidemia, HbA1c and inflammation.The above findings therefore point out towards the importance of a comprehensive metabolic approach in such subpopulations. For instance, personalized glycemic control interventions and lipid management can be tailored to them to improve outcomes. Therefore more Study is still needed on the mechanisms underlying metabolic syndrome so as to develop efficient clinical approaches for managing these complications better.

Abstract 96 | PDF Downloads 19

References

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339:229-234. doi:10.1056/NEJM199807233390404
2. Malmberg K, Yusuf S, Gerstein HC, et al.: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000, 102:1014-1019. doi:10.1161/01.CIR.102.9.1014
3. Norhammar A, Tenerz A, Nilsson G, et al.: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359:2140-2144. doi:10.1016/S0140-6736(02)09089-X
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352:837-853. doi:10.1016/S0140-6736(98)07019-6
5. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004, 364:685-696. doi:10.1016/S0140-6736(04)16895-5
6. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004, 109:2818-2825. doi:10.1161/01.CIR.0000128356.29645.9C
7. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004, 109:2818-2825. doi:10.1161/01.CIR.0000128356.29645.9C
8. Skyler JS, Bergenstal R, Bonow RO, et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. J Am Coll Cardiol. 2009, 53:298-304. doi:10.1016/j.jacc.2008.10.008
9. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358:2545-2559. doi:10.1056/NEJMoa0802743
10. Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999, 100:1134-1146. doi:10.1161/01.CIR.100.10.1134
11. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004, 364:685-696. doi:10.1016/S0140-6736(04)16895-5
12. Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006, 83:456S-460S. doi:10.1093/ajcn/83.2.456S
13. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med. 1999, 340:115-126. doi:10.1056/NEJM199901143400207
14. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002, 347:1557-1565. doi:10.1056/NEJMoa021993
15. Rydén L, Standl E, Bartnik M, et al.: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007, 28:88-136. doi:10.1093/eurheartj/ehl260
16. Anand SS, Islam S, Rosengren A, et al.: Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008, 29:932-940. doi:10.1093/eurheartj/ehn018
17. Gaede P, Lund-Andersen H, Parving HH, et al.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358:580-591. doi:10.1056/NEJMoa0706245